Clinical trials: Thromboembolic Disease
Venous Thromboembolism, Venous Thrombosis
Educating Nurses About Venous Thromboembolism (VTE) Prevention
As part of mandatory on-going nursing education, the investigators have incorporated identical information into two distinct web-based learning formats - the traditional linear PowerPoint format (with voice-over) and a new…
- Trial name
- NCT02301793
- Testing
- Nurse education in contemporary format, Nurse education in traditional format
- Where
- United States
- Volunteers
- 933 people
- Sponsor
- Johns Hopkins University
Thromboembolism
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the efficacy and the safety for HFS.
- Trial name
- NCT00320424
- Testing
- Fondaparinux
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Embolism, Pulmonary
The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
The primary objective is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of GSK576428 as…
- Trial name
- NCT00981409
- Testing
- Fondaparinux sodium, unfractionated heparin (UFH)
- Where
- 27 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Deep Vein Thrombosis, Venous Thrombosis
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic…
- Conditions
- Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism
- Trial name
- ATTRACT (NCT00790335)
- Testing
- Recombinant tissue plasminogen activator (rt-PA)
- Where
- 56 sites in United States
- Volunteers
- 692 people
- Sponsor
- Washington University School of Medicine
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Venous Thromboembolism
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE.
- Trial name
- NCT02596230
- Where
- 222 sites in United States, Argentina and 35 more
- Volunteers
- 7,797 people
- Sponsor
- Boehringer Ingelheim
Anticoagulants, Atrial Fibrillation
Improving Anticoagulation Control in VISN 1
Over 100,000 VHA patients receive anticoagulants (blood thinners) each year to prevent blood clots (including strokes). Too much anticoagulation increases the risk of serious or even fatal bleeding, and too little anticoagulation…
- Conditions
- Anticoagulants, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- NCT01653405
- Testing
- Multifaceted behavioral intervention
- Where
- United States
- Volunteers
- 1,260,576 people
- Sponsor
- VA Office of Research and Development
Hypertension
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
This is an open label, long term extension to Study AMB115811. All subjects may remain in the extension study for a minimum of 18 months.
- Trial name
- AMBER II (NCT01894022)
- Testing
- Ambrisentan 5 mg
- Where
- 50 sites in United States, Argentina and 14 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Atrial Fibrillation, Venous Thromboembolism
Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients
Warfarin is very effective for the prevention of blood clots (thrombosis). A test of coagulation, the prothrombin time (PT) is used to monitor the effect.
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction
- Trial name
- FORESPEAK-0 (NCT00814177)
- Testing
- warfarin
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Hamilton Health Sciences Corporation
Acute Pulmonary Embolism, Thromboembolism
SYMPHONY-PE Study for Treatment of Pulmonary Embolism
Evaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism
- Conditions
- Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis
- Trial name
- NCT06062329
- Testing
- Symphony Thrombectomy System
- Where
- 19 sites in United States
- Volunteers
- 110 people
- Sponsor
- Imperative Care, Inc.
Blood Clot, Trauma
PREVENTion of Clot in Orthopaedic Trauma
The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.
- Trial name
- PREVENT CLOT (NCT02984384)
- Testing
- Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH)
- Where
- 21 sites in United States, Canada
- Volunteers
- 12,424 people
- Sponsor
- Major Extremity Trauma Research Consortium
Venous Thromboembolism
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
To investigate the safety and tolerability of dabigatran etexilate solution in children and to obtain preliminary pharmacokinetic/pharmacodynamic data
- Trial name
- NCT01083732
- Testing
- dabigatran etexilate
- Where
- 7 sites in Canada, Italy and 4 more
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT02923115
- Testing
- DS-1040b, Enoxaparin
- Where
- 46 sites in United States, Austria and 6 more
- Volunteers
- 134 people
- Sponsor
- Daiichi Sankyo
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
- Trial name
- CHEST-1 (NCT00855465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 89 sites in United States, Argentina and 24 more
- Volunteers
- 262 people
- Sponsor
- Bayer
Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 4 (NCT00362232)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 124 sites in United States, Bulgaria and 11 more
- Volunteers
- 3,148 people
- Sponsor
- Bayer
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03080883
- Testing
- Apixaban
- Where
- 32 sites in United States
- Volunteers
- 370 people
- Sponsor
- Academic and Community Cancer Research United
Deep Vein Thrombosis
Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
The purpose of this study is to determine how frequently children undergoing elective neurosurgical procedures develop blood clots in the deep veins of the legs while hospitalized.
- Trial name
- NCT02037607
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Indiana University
Anticoagulants and Bleeding Disorders, Surgery
Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin
The main objective of this study is to determine the time interval following the last treatment dose of enoxaparin at which the amount of anti-Xa level activity is reliably less than 0.2 international unit per milliliter (IU/mL)…
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
- Trial name
- NCT03296033
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Wake Forest University Health Sciences
Venous Thromboembolism
A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement (TKR) surgery.
- Trial name
- ROXI-VTE II (NCT06454630)
- Testing
- REGN7508, Enoxaparin
- Where
- 14 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 179 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion